Drug Trial Radar · NCT04740476
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 20, 2021
Primary completion
Mar 31, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Stoke Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
Conditions
- Dravet Syndrome
Interventions
zorevunersen (STK-001)Drug
zorevunersen drug product is an antisense oligonucleotide administered as an intrathecal injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of multiple doses of zorevunersenTime frame: Screening (Day -1) until 6 months after multiple drug dosing
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco Medical Center
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
Nicklaus Children's Hospital
Miami, Florida
Florida Hospital for Children
Orlando, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Iowa Children's Hospital
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Michigan Medicine
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
NYU Comprehensive Epilepsy Center
New York, New York
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UT LeBonheur Pediatric Specialists, Inc.
Memphis, Tennessee
Cook Children's Medical Center
Fort Worth, Texas
Seattle Children's Hospital
Seattle, Washington
MultiCare Health System Institute for Research and Innovation
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.